Mutation detail:
| Mutation site | 17259G>T |
| Virus | SARS-CoV-2 |
Mutation level  |
Nucleotide level |
| Gene/protein/region type | ORF1ab(helicase) |
| Gene ID | 43740578 |
| Country | - |
| Mutation type |
- |
| Genotype/subtype/clade | 20J |
| Sample |
Human |
| Variants | Gamma |
| Viral reference sequence | NC_045512.2 |
| Drug/antibody/vaccine | - |
| Transmissibility |
- |
| Transmission mechanism | - |
| Pathogenicity |
- |
| Pathogenicity mechanism | - |
| Immune escape mutation | - |
| Immune escape mechanism | - |
| RT-PCR primers probes | - |
Protein detail:
| Protein name | ORF1ab polyprotein |
| Uniprot protein ID | P0DTC1 |
| Protein length | 7096 amino acids |
| Protein description | ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
Literature information:
| Pubmed ID | 34493762 |
| Clinical information | No |
| Disease | - |
| Published year | 2021 |
| Journal | Scientific Reports |
| Title | Dynamics of SARS-CoV-2 mutations reveals regional-specificity and similar trends of N501 and high-frequency mutation N501Y in different levels of control measures |
| Author | Santiago Justo Arevalo,Daniela Zapata Sifuentes,Cesar J Huallpa,Gianfranco Landa Bianchi, Adriana Castillo Chavez |
| Evidence | We identified 115 mutations with NRFp>0.03 (Fig. S1); this means that those mutations are estimated to be present in more than 3% of the COVID-19 cases globally. Considering that the sum of the reported cases from the 714 country-month combinations analyzed was 120,008,410 cases, an NRFp of more than 0.03 means that those mutations were present in more than 3,600,252 global COVID-19 cases. |